<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="116167">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02142868</url>
  </required_header>
  <id_info>
    <org_study_id>A5481034</org_study_id>
    <nct_id>NCT02142868</nct_id>
  </id_info>
  <brief_title>Expanded Access Study Of Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate</brief_title>
  <official_title>An Expanded Access Study Of Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To provide access to palbociclib to post-menopausal women with HR-positive, HER2-negative
      advanced breast cancer who are deemed appropriate for letrozole therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Accepting interested sites; not yet open for participant recruitment.
    </textblock>
  </detailed_description>
  <overall_status>Temporarily not available</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Expanded Access</study_type>
  <study_design>N/A</study_design>
  <condition>Advanced Breast Cancer (Female)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib</intervention_name>
    <description>Palbociclib will be administered orally once a day at 125 mg/day for 21 days followed by 7 days off treatment for each 28-day cycle (Schedule 3/1)</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Letrozole will be administered orally at 2.5 mg once daily as continuous daily dosing schedule according to product labeling and in compliance with its local prescribing information.</description>
    <other_name>Femara</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Post-menopausal women 18 years of age or above with proven diagnosis of advanced
             adenocarcinoma of the breast (locoregionally recurrent or metastatic disease)

          -  ER-positive and/or PR-positive tumor based on local laboratory results

          -  HER2-negative tumor based on local laboratory results

          -  Patients must be appropriate candidates for letrozole therapy

        Exclusion Criteria:

          -  Patients who have previously participated in a palbociclib trial or who have received
             prior treatment with any CDK inhibitor
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A5481034&amp;StudyName=Expanded%20Access%20Study%20Of%20Palbociclib%20In%20Combination%20With%20Letrozole%20As%20Treatment%20Of%20Post-Menopausal%20Women%20With%20HR-Positive%2C%20Her2-Negative%20A</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 21, 2014</lastchanged_date>
  <firstreceived_date>May 16, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Expanded Access</keyword>
  <keyword>Advanced Breast Cancer</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
